A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

• Status: NOT_YET_RECRUITING
• Trial end date: 2029-07-31

Summary

This study will be conducted to compare Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.

• Phase: PHASE2

Details

• Lead Sponsor: Incyte Corporation
• Treatments: axatilimab; Calcineurin Inhibitors; Cyclosporine; Everolimus; ibrutinib; Imatinib Mesylate; Methotrexate; Mycophenolic Acid; Photopheresis; Rituximab; Sirolimus; Tacrolimus